DK0510003T3 - Piperidin-og pyrrolidinderivater - Google Patents

Piperidin-og pyrrolidinderivater

Info

Publication number
DK0510003T3
DK0510003T3 DK90917305.6T DK90917305T DK0510003T3 DK 0510003 T3 DK0510003 T3 DK 0510003T3 DK 90917305 T DK90917305 T DK 90917305T DK 0510003 T3 DK0510003 T3 DK 0510003T3
Authority
DK
Denmark
Prior art keywords
alkyl
pct
formula
group
independently
Prior art date
Application number
DK90917305.6T
Other languages
English (en)
Inventor
David Alker
Peter Edward Cross
Original Assignee
Pfizer
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Pfizer Ltd filed Critical Pfizer
Application granted granted Critical
Publication of DK0510003T3 publication Critical patent/DK0510003T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK90917305.6T 1990-01-06 1990-11-28 Piperidin-og pyrrolidinderivater DK0510003T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909000301A GB9000301D0 (en) 1990-01-06 1990-01-06 Piperidine & pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
DK0510003T3 true DK0510003T3 (da) 1996-01-29

Family

ID=10668922

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90917305.6T DK0510003T3 (da) 1990-01-06 1990-11-28 Piperidin-og pyrrolidinderivater

Country Status (14)

Country Link
US (1) US5344835A (da)
EP (1) EP0510003B1 (da)
JP (1) JPH0692365B2 (da)
AT (1) ATE128463T1 (da)
CA (1) CA2067758C (da)
DE (1) DE69022744T2 (da)
DK (1) DK0510003T3 (da)
ES (1) ES2078356T3 (da)
FI (1) FI922341A (da)
GB (1) GB9000301D0 (da)
GR (1) GR3017944T3 (da)
IE (1) IE69312B1 (da)
PT (1) PT96421B (da)
WO (1) WO1991010650A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CN1290251A (zh) * 1998-02-04 2001-04-04 万有制药株式会社 N-酰基环胺衍生物
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
JP4932994B2 (ja) * 1999-04-07 2012-05-16 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 抗癌性カルシウムチャンネル遮断薬
WO2001098266A2 (en) * 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US8017791B2 (en) * 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
WO2005007645A1 (en) * 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
EP1725525A1 (en) * 2004-03-11 2006-11-29 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7250414B2 (en) * 2004-03-11 2007-07-31 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7915433B2 (en) * 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE934890C (de) * 1951-10-07 1955-11-10 Chem Fab Promonta Ges Mit Besc Verfahren zur Herstellung von basischen Benzhydrylaethern
GB780027A (en) * 1955-01-20 1957-07-31 Schering Corp 3-piperidyl ethers and thioethers
US2974146A (en) * 1956-02-24 1961-03-07 Lakeside Lab Inc 3-piperidyl benzhydryl ethers
EP0228893A3 (en) * 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
US4810713A (en) * 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
GB8816365D0 (en) * 1988-07-08 1988-08-10 Pfizer Ltd Therapeutic agents
EP0370629B2 (en) * 1988-11-21 1998-01-07 Zeneca Limited Fungicides

Also Published As

Publication number Publication date
ATE128463T1 (de) 1995-10-15
DE69022744D1 (de) 1995-11-02
FI922341A0 (fi) 1992-05-22
GB9000301D0 (en) 1990-03-07
CA2067758C (en) 1994-12-13
FI922341A (fi) 1992-05-22
JPH0692365B2 (ja) 1994-11-16
EP0510003A1 (en) 1992-10-28
PT96421A (pt) 1991-10-15
IE910020A1 (en) 1991-07-17
GR3017944T3 (en) 1996-02-29
JPH05501560A (ja) 1993-03-25
PT96421B (pt) 1997-05-28
ES2078356T3 (es) 1995-12-16
US5344835A (en) 1994-09-06
CA2067758A1 (en) 1991-07-07
WO1991010650A1 (en) 1991-07-25
IE69312B1 (en) 1996-09-04
EP0510003B1 (en) 1995-09-27
DE69022744T2 (de) 1996-03-07

Similar Documents

Publication Publication Date Title
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
DE69014901T2 (de) Muscarin-rezeptor-antagonisten.
CA2328780A1 (en) Dihydropyrimidines
DE69327541T2 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
EP0335979A4 (en) Thienopyrimidine derivatives
AU4258389A (en) Muscarinic receptor antagonists
DE69510510D1 (de) N-benzoylmethylsubstituierte paroxetinderivate
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
KR960007560A (ko) 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
ATE108776T1 (de) Muscarin-rezeptor-antagonisten.
NZ304988A (en) 1-omega-(3,4-dihydro-2-naphthalenyl)alkyl] cyclic amine derivatives and their use
DK0553278T3 (da) 2-Phenyl- og 2-thienyl-(2)-piperidinderivater med neurobeskyttende egenskaber
DE69532187D1 (de) Abeo-ergolinderivate als 5ht1a liganden
CA2069931A1 (en) Muscarinic receptor antagonists